FOCUSED ON DEVELOPMENT OF ADVANCED SOLUTIONS FOR REGENERATIVE SURGICAL PATCHES AND ADHESIVES

PRODUCT TIMELINE

Nurami’s preliminary product is ArtiFascia®, a highly effective surgical patch with an integrated, temperature sensitive, non-porous barrier film. ArtiFascia® has successfully completed pivotal clinical trials in 85 participants, including a 6-month follow-up, has been FDA cleared, and is avaialble for purchase in the US.
Our pipeline includes ArtiFix®, a soft tissue sealant patch, which is designed to not require suturing and NovaFibreXTM, a ground-breaking surgical adhesive for general surgery, which will be designed to withstand premature degradation while adhering effectively to the wet environment of internal organs.

*ArtiFix and NovaFibreX are for investigational use only

Product

Surgery
Type

Device
Development

Preclinical
Studies

Pilot Clinical
Trials

Pivotal Clinical
Trials

Regulatory
Clearance

Commercialization

Neurosurgery

FDA cleared in 2023

CE in 2024

2023

Neuro &
general surgery

2024

General
surgery

Product

Surgery
Type

Device
Development

Preclinical
Studies

Pilot Clinical
Trials

Pivotal Clinical
Trials

Regulatory
Clearance

Commercialization

Neurosurgery

FDA and
CE in 2022

2023

Neuro &
general surgery

2023

General
surgery

Surgery
Type

Neurosurgery

Neuro &
general surgery

General
surgery

Device
Development

Preclinical
Studies

Pilot Clinical Trials

2023

Pivot Clinical Trials

Regulatory
Clearance

FDA and
CE in 2023

Commercialization

2023

Commerci-
alization

2022